Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High CD56++CD16- natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort.
Bayigga L, Nabatanzi R, Sekiziyivu PN, Mayanja-Kizza H, Kamya MR, Kambugu A, Olobo J, Kiragga A, Kirimunda S, Joloba M, Nakanjako D. Bayigga L, et al. Among authors: joloba m. BMC Immunol. 2014 Jan 31;15:2. doi: 10.1186/1471-2172-15-2. BMC Immunol. 2014. PMID: 24483185 Free PMC article.
CD4 T-cell activation and reduced regulatory T-cell populations are associated with early development of cataracts among HIV-infected adults in Uganda.
Nakanjako D, Otiti-Sengeri J, Ssewanyana I, Nabatanzi R, Bayigga L, Kirimunda S, Joloba M, Manabe YC, Kambugu A, Colebunders R, Mayanja-Kizza H. Nakanjako D, et al. Among authors: joloba m. Immunol Lett. 2014 Sep;161(1):44-9. doi: 10.1016/j.imlet.2014.04.011. Epub 2014 Apr 28. Immunol Lett. 2014. PMID: 24785834 Free PMC article.
Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.
Nabatanzi R, Bayigga L, Ssinabulya I, Kiragga A, Kambugu A, Olobo J, Joloba M, Kamya MR, Mayanja-Kizza H, Nakanjako D. Nabatanzi R, et al. Among authors: joloba m. Immunol Lett. 2014 Dec;162(2 Pt B):264-72. doi: 10.1016/j.imlet.2014.09.016. Epub 2014 Sep 26. Immunol Lett. 2014. PMID: 25263953 Free PMC article. Clinical Trial.
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Nakanjako D, Ssinabulya I, Nabatanzi R, Bayigga L, Kiragga A, Joloba M, Kaleebu P, Kambugu AD, Kamya MR, Sekaly R, Elliott A, Mayanja-Kizza H. Nakanjako D, et al. Among authors: joloba m. Trop Med Int Health. 2015 Mar;20(3):380-90. doi: 10.1111/tmi.12442. Epub 2015 Jan 6. Trop Med Int Health. 2015. PMID: 25441397 Free PMC article. Clinical Trial.
Capacity for science in sub-Saharan Africa.
Elliott A, Nerima B, Bagaya B, Kambugu A, Joloba M, Cose S, Pantaleo G, Yazdanbakhsh M, Mabey D, Dunne D, Moffett A, Rwakishaya EK, Kaleebu P, Mbidde EK. Elliott A, et al. Among authors: joloba m. Lancet. 2015 Jun 20;385(9986):2435-7. doi: 10.1016/S0140-6736(15)61111-4. Lancet. 2015. PMID: 26122054 No abstract available.
Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology.
Nakiyingi L, Nonyane BA, Ssengooba W, Kirenga BJ, Nakanjako D, Lubega G, Byakika-Kibwika P, Joloba ML, Ellner JJ, Dorman SE, Mayanja-Kizza H, Manabe YC. Nakiyingi L, et al. PLoS One. 2015 Jul 29;10(7):e0133756. doi: 10.1371/journal.pone.0133756. eCollection 2015. PLoS One. 2015. PMID: 26222142 Free PMC article.
Immunology in Africa.
Cose S, Bagaya B, Nerima B, Joloba M, Kambugu A, Tweyongyere R, Dunne DW, Mbidde E, Kaleebu P, Elliott AM. Cose S, et al. Among authors: joloba m. Trop Med Int Health. 2015 Dec;20(12):1771-7. doi: 10.1111/tmi.12599. Epub 2015 Oct 12. Trop Med Int Health. 2015. PMID: 26391634 Free PMC article.
345 results